Cargando…

PRAME expression and promoter hypomethylation in epithelial ovarian cancer

PRAME is a cancer-testis antigen (CTA) and potential immuno-therapeutic target, but has not been well-studied in epithelial ovarian cancer (EOC) or its high grade serous (HGSC) subtype. Compared to normal ovary, PRAME expression was significantly increased most EOC, regardless of stage and grade. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wa, Barger, Carter J., Eng, Kevin H., Klinkebiel, David, Link, Petra A., Omilian, Angela, Bshara, Wiam, Odunsi, Kunle, Karpf, Adam R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216727/ https://www.ncbi.nlm.nih.gov/pubmed/27322684 http://dx.doi.org/10.18632/oncotarget.9977

Ejemplares similares

Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability
por: Zhang, Wa, et al.
Publicado: (2020)

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2015)

Expression of the POTE gene family in human ovarian cancer
por: Barger, Carter J, et al.
Publicado: (2018)

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression
por: Barger, Carter J., et al.
Publicado: (2015)

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
por: Thaker, Premal H., et al.
Publicado: (2021)

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
por: Paluch, Benjamin E, et al.
Publicado: (2016)

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
por: Liu, Cassie, et al.
Publicado: (2021)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer
por: Barger, Carter J, et al.
Publicado: (2021)

Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2020)

Prognostic value of histone chaperone FACT subunits expression in breast cancer
por: Attwood, Kristopher, et al.
Publicado: (2017)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Association between global DNA hypomethylation in leukocytes and risk of breast cancer
por: Choi, Ji-Yeob, et al.
Publicado: (2009)

Transmission of X-linked Ovarian Cancer: Characterization and Implications
por: Etter, John Lewis, et al.
Publicado: (2020)

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease
por: Strohl, Anna, et al.
Publicado: (2016)

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
por: Daudi, Sayeema, et al.
Publicado: (2014)

Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages
por: Aikhionbare, Felix O, et al.
Publicado: (2007)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer
por: Seagle, Brandon-Luke L., et al.
Publicado: (2016)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas
por: Bui, Chau M., et al.
Publicado: (2021)

PRAME expression is similar in scar and desmoplastic melanoma
por: Plotzke, Jaclyn M., et al.
Publicado: (2022)

PRAME induces genomic instability in uveal melanoma
por: Kurtenbach, Stefan, et al.
Publicado: (2023)

Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer
por: Barger, Carter J, et al.
Publicado: (2019)

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015)

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer
por: Starbuck, Kristen D., et al.
Publicado: (2018)

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2(Prame) complex
por: Zhang, Wenjuan, et al.
Publicado: (2021)

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock
por: Muto, Yusuke, et al.
Publicado: (2020)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples
por: Ronchi, Andrea, et al.
Publicado: (2022)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
por: Glutsch, Valerie, et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

Genetic mechanism for the loss of PRAME in B cell lymphomas
por: Mraz, Marek
Publicado: (2022)

PRAME Expression in Mucosal Melanoma of the Head and Neck Region
por: Ricci, Costantino, et al.
Publicado: (2023)

Molecular and clinicopathological implications of PRAME expression in adult glioma
por: Le, Minh-Khang, et al.
Publicado: (2023)

Intrinsic disorder in PRAME and its role in uveal melanoma
por: Antonietti, Michael, et al.
Publicado: (2023)

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l3khjbvefo3cf7p3l81obokt02